<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Hepatol</journal-id><journal-id journal-id-type="iso-abbrev">J. Hepatol</journal-id><journal-title-group><journal-title>Journal of Hepatology</journal-title></journal-title-group><issn pub-type="ppub">0168-8278</issn><issn pub-type="epub">1600-0641</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22326464</article-id><article-id pub-id-type="pmc">3355301</article-id><article-id pub-id-type="publisher-id">S0168-8278(12)00113-4</article-id><article-id pub-id-type="doi">10.1016/j.jhep.2012.01.020</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>The effect of steroid pretreatment of deceased organ donors on liver allograft function: A blinded randomized placebo-controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Amatschek</surname><given-names>Stefan</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn1" ref-type="fn">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Wilflingseder</surname><given-names>Julia</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="fn1" ref-type="fn">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Pones</surname><given-names>Mario</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="fn1" ref-type="fn">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Kainz</surname><given-names>Alexander</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name><surname>Bodingbauer</surname><given-names>Martin</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>M&#x000fc;hlbacher</surname><given-names>Ferdinand</given-names></name><xref rid="aff3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name><surname>Langer</surname><given-names>Robert M.</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Gerlei</surname><given-names>Zsuzsanna</given-names></name><xref rid="aff4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name><surname>Oberbauer</surname><given-names>Rainer</given-names></name><email>rainer.oberbauer@meduniwien.ac.at</email><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib></contrib-group><aff id="aff1"><label>1</label>KH Elisabethinen, Linz, Austria</aff><aff id="aff2"><label>2</label>Department of Internal Medicine 3, Medical University of Vienna, Austria</aff><aff id="aff3"><label>3</label>Department of Transplantation, Medical University of Vienna, Austria</aff><aff id="aff4"><label>4</label>Department of Transplantation and Surgery, Semmelweis University, Budapest, Hungary</aff><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author. Address: Department of Internal Medicine 3, Medical University of Vienna, W&#x000e4;hringer G&#x000fc;rtel 18&#x02013;20, 1090 Vienna, Austria. Tel.: +43 1 40400 4390; fax: +43 1 40400 4392. <email>rainer.oberbauer@meduniwien.ac.at</email></corresp><fn id="fn1"><label>&#x02020;</label><p>These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>1</day><month>6</month><year>2012</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="ppub">.--><pub-date pub-type="ppub"><month>6</month><year>2012</year></pub-date><volume>56</volume><issue>6</issue><fpage>1305</fpage><lpage>1309</lpage><history><date date-type="received"><day>17</day><month>10</month><year>2011</year></date><date date-type="rev-recd"><day>12</day><month>1</month><year>2012</year></date><date date-type="accepted"><day>23</day><month>1</month><year>2012</year></date></history><permissions><copyright-statement>&#x000a9; 2012 Elsevier B.V.</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>European Association for the Study of the Liver</copyright-holder><license xlink:href="https://creativecommons.org/licenses/by/4.0/"><license-p>Open Access under <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">CC BY 4.0</ext-link> license</license-p></license></permissions><abstract><sec><title>Background &#x00026; Aims</title><p>Brain death-associated inflammatory response contributes to increased risk of impaired early liver allograft function, which might be counterbalanced by steroid pretreatment of the organ donor. The aim of this randomized controlled trial was to elucidate whether steroid pretreatment of liver donors improves early liver allograft function, prevents rejection and prolongs survival.</p></sec><sec><title>Methods</title><p>A placebo-controlled blinded randomized clinical trial was performed in three different centers in Austria and Hungary between 2006 and 2008. Ninety deceased organ donors received either 1000&#x000a0;mg of methylprednisolone or placebo 6&#x000a0;h before recovery of organs. The primary end point was the concentration slope of transaminases within the first week. The secondary end point included survival and biopsy-confirmed acute rejection (BCAR) within 3 years after transplantation.</p></sec><sec><title>Results</title><p>Of the 90 randomized donors, 83 recipients were eligible for study. The trajectories of ALT and AST were not different between treatments (<italic>p</italic>&#x000a0;=&#x000a0;0.40 and <italic>p</italic>&#x000a0;=&#x000a0;0.13, respectively). Eight subjects died in the steroid and 13 in the placebo group within 3 years after engraftment (RR&#x000a0;=&#x000a0;0.63 95% CI [0.29,&#x000a0;1.36], <italic>p</italic>&#x000a0;=&#x000a0;0.31). Eleven recipients experienced biopsy-confirmed rejection (BCAR) in the steroid and 11 in the placebo group (RR&#x000a0;=&#x000a0;1.02 95% CI [0.50,&#x000a0;2.10], <italic>p</italic>&#x000a0;=&#x000a0;1.00). No effect modification could be identified in the predefined strata of donor age, sex, cold ischemic time, and cause of donor death.</p></sec><sec><title>Conclusions</title><p>Steroid pretreatment of organ donors did not improve outcomes after liver transplantation.</p></sec></abstract><kwd-group><title>Abbreviations</title><kwd>BCAR, biopsy-confirmed rejection</kwd><kwd>ALT, alanine transaminase</kwd><kwd>AST, aspartate transaminase</kwd><kwd>GGT, glutamyl transpeptidase</kwd><kwd>AP, alkaline phosphatase</kwd><kwd>RAI, reaction activity index</kwd><kwd>BIL, total bilirubin</kwd><kwd>ALB, serum albumin</kwd></kwd-group><kwd-group><title>Keywords</title><kwd>Liver transplantation</kwd><kwd>Steroid</kwd><kwd>Donor pretreatment</kwd><kwd>Early liver allograft function</kwd></kwd-group></article-meta></front><body><sec sec-type="intro" id="s0005"><title>Introduction</title><p>Liver transplantation is the only available treatment of end stage liver disease. However, a raising demand for liver transplant organs has increased the median waiting time for liver allografts in the Eurotransplant region from 4 months in 2000 to 14&#x000a0;months in 2009 <xref rid="b0005" ref-type="bibr">[1]</xref>. Even worse, approximately 20% of all patients on the waiting list for liver transplantation died in 2009.</p><p>Thus donor criteria have been liberalized in the last decade as a consequence of the imbalance between supply and demand. For example, the median age of liver donors increased from 26 to 52&#x000a0;years between 1990 and 2009. While donor age has been considered a major risk factor for long time graft survival <xref rid="b0010 b0015" ref-type="bibr">[2,3]</xref>, there is an increasing evidence that also consequences of donor brain death in the graft might exert adverse effects on transplant recipients.</p><p>It has been shown in kidney transplantation that graft survival from living donors is significantly longer when compared to deceased donor allografts <xref rid="b0020 b0025" ref-type="bibr">[4,5]</xref>. Furthermore, brain death triggers a complex series of pathophysiological changes that also drive alterations of gene expression in transplant organs <xref rid="b0030 b0035 b0040 b0045 b0050" ref-type="bibr">[6&#x02013;10]</xref>, although donor organs derived from living or deceased donors cannot be distinguished on a morphological basis. We previously showed in kidney grafts that gene expression profiles derived from deceased organs are characterized by a severe pro-inflammatory state which is not observed in organs from living donors <xref rid="b0055" ref-type="bibr">[11]</xref>.</p><p>Recently, we elucidated that pretreatment of deceased organ donors with corticosteroids led to a significant reduction of the molecular inflammation signature in transplant kidneys even though the rate of delayed graft function remained unchanged <xref rid="b0060" ref-type="bibr">[12]</xref>.</p><p>The influence of steroid pretreatment on the outcome after liver transplantation has been evaluated in a previous study <xref rid="b0065" ref-type="bibr">[13]</xref>. In this publication, the authors claimed that steroid donor treatment significantly ameliorated ischemia reperfusion injury determined by AST levels on day one after transplantation. However, the effect of steroid pretreatment on the genome wide inflammatory signature as well as the trajectories of transaminases and hard long-term outcomes remained elusive.</p><p>Thus, the goal of the present study was to test in a blinded, randomized, placebo-controlled clinical trial whether steroid pretreatment of the deceased organ donor caused a reduced release of transaminase from the donor liver and subsequently less rejection and longer survival.</p></sec><sec sec-type="materials|methods" id="s0010"><title>Materials and methods</title><sec id="s0015"><title>Study design</title><p>The liver grafts recovered from multiorgan donors of our recently published randomized, blinded, placebo-controlled trial were evaluated <xref rid="b0060" ref-type="bibr">[12]</xref>. The trial is registered under controlled-trials.com registration number <ext-link ext-link-type="uri" xlink:href="ctgov:ISRCTN78828338">ISRCTN78828338</ext-link>. Out of the total eligible donors (n&#x000a0;=&#x000a0;269), 90 liver donors (39 from Vienna, 39 from Budapest and 5 from Linz) were randomized equally in the steroid or placebo group. The detailed CONSORT criteria can be found in Kainz <italic>et al.</italic>
<xref rid="b0060" ref-type="bibr">[12]</xref>. Briefly, after brain death was declared, deceased donors received either a single injection of 1000&#x000a0;mg methylprednisolone or placebo (0.9% saline) between 6 and 3&#x000a0;h before organ recovery. All organs were perfused with a histidine-ketoglutarate preservation solution during organ procurement. Liver transplant recipients from the transplant centers in Vienna (Austria) and Budapest (Hungary) were included in our trial. The donor demographics were collected at the study website <ext-link ext-link-type="uri" xlink:href="http://www.meduniwien.ac.at/nephrogene/trials/">http://www.meduniwien.ac.at/nephrogene/trials/</ext-link> and the liver recipient demographics and follow-up data of the recipient were collected by the local transplant coordinators.</p><p>Donors were equally randomized to steroid or placebo treatment based on a permuted block design with block sizes of four (<ext-link ext-link-type="uri" xlink:href="https://www.meduniwien.ac.at/randomizer">https://www.meduniwien.ac.at/randomizer</ext-link>). Central randomization was stratified for donor age above 50&#x000a0;years through our study website and concealed until data analysis. The randomization order did not have a repeating sequence and the randomization code was not revealed to recipients or investigators. The local transplant coordinators, enrolled donors, recipients and investigators were blinded for the allograft treatment.</p><p>The study protocol was approved by the institutional review board (Ethical Committee of the Medical University of Vienna, Vienna, Austria [study protocol EK-067/2005; to be found at <ext-link ext-link-type="uri" xlink:href="http://ohrp.cit.nih.gov/search">http://ohrp.cit.nih.gov/search</ext-link>]), TUKEB-Hungary and Eurotransplant (study protocol 6021KAC06) at each study site.</p></sec><sec id="s0020"><title>Outcomes and sample size calculation</title><p>Our primary end point was the serum level trajectories of transaminases (alanine transaminase (ALT) and aspartate transaminase (AST)) within the first week after engraftment.</p><p>We calculated a detectable difference in the slopes of 0.65 between the groups at a standard deviation of 0.3, a correlation coefficient of 0.7 in the sequential individual measurements and the assumption that a slope of the log transformed AST levels in the first week is 0.5. Study power was 80% at an alpha value of 0.05 assuming a 10% drop-out rate to detect such difference. Exclusion criteria were fulminant liver failure, multiorgan transplantation or retransplantation and HIV-positive recipients.</p><p>Liver specific data, which were recorded daily in the first week of the trial, included gamma glutamyl transpeptidase (GGT), alkaline phosphatase (AP), albumin as well as total bilirubin.</p><p>The secondary end point included graft loss, mortality and BCAR (Rejection Activity Index (RAI) score &#x02a7e;3) within 3 years after transplantation.</p><p>Effect modification of the predefined subgroups donor age, sex, cold ischemic time, and cause of donor death were evaluated by interaction analyses.</p></sec><sec id="s0025"><title>Statistical analysis</title><p>Demographic baseline characteristics were compared using <italic>t</italic> tests for continuous data and Chi-square tests or Fisher exact tests for categorical data. Trajectories of various liver parameters after transplantation were analyzed using a linear mixed model with time, therapy as well as the transplantation center as independent variables. Kaplan&#x02013;Meier plots were used to visualize time to acute rejection episodes and the combined graft loss/death. Differences between groups were calculated by the log-rank test. Data are provided as mean&#x000a0;&#x000b1;&#x000a0;SD if not otherwise indicated. <italic>p</italic> values&#x000a0;&#x0003c;0.05 were considered to be statistically significant. All analyses were performed with SAS for Windows 9.2 (Cary, NJ, USA).</p></sec></sec><sec sec-type="results" id="s0030"><title>Results</title><sec id="s0035"><title>Baseline characteristics of organ donors and recipients</title><p>Of the 90 randomized donors, seven allografts were allocated to recipients with study exclusion criteria (2 retransplant, 2 simultaneous kidney and liver, 3 high urgency transplantations). Of the remaining 83 donor organs, 41 organs were procured from steroid treated and 42 from placebo treated donors between 2006 and 2008 (see CONSORT flowchart in <xref rid="f0005" ref-type="fig">Fig. 1</xref>). Age, sex and clinical indices of donors and recipients are provided in <xref rid="t0005" ref-type="table">Table 1</xref>. Mean donor age and recipient age were not different in both groups (47&#x000a0;&#x000b1;&#x000a0;12 and 48&#x000a0;&#x000b1;&#x000a0;13&#x000a0;years in the placebo group <italic>vs.</italic> 46&#x000a0;&#x000b1;&#x000a0;12 and 49&#x000a0;&#x000b1;&#x000a0;9&#x000a0;years in the treatment group). Accordingly, mean MELD score of the recipient and cold ischemic time did not reveal significant differences between the study arms (16&#x000a0;&#x000b1;&#x000a0;6 and 440&#x000a0;&#x000b1;&#x000a0;123&#x000a0;min in the control group <italic>vs.</italic> 15&#x000a0;&#x000b1;&#x000a0;6 and 444&#x000a0;&#x000b1;&#x000a0;136&#x000a0;min in the steroid group).</p><p>The immunosuppressive regime of all subjects included 40&#x000a0;mg dexamethasone intraoperatively, 3 days of ATG induction (Thymoglobuline&#x000ae;, Genzyme 2.5&#x000a0;mg/kg/d) and CNI maintenance therapy. Rejections were treated with 3 days of 500&#x000a0;mg prednisolone.</p></sec><sec id="s0040"><title>Primary and secondary study end points</title><p>Biochemical indicators of liver cell necrosis over the first week are depicted in <xref rid="f0010" ref-type="fig">Fig. 2</xref>. Trajectories of alanine and aspartate transaminases (ALT and AST) were not different between the two treatment groups (<italic>p</italic>&#x000a0;=&#x000a0;0.40 and <italic>p</italic>&#x000a0;=&#x000a0;0.13, respectively). Mean ALT levels decreased between day 1 and day 7 post-transplantation from 784&#x000a0;&#x000b1;&#x000a0;1025 U/L to 156&#x000a0;&#x000b1;&#x000a0;148 U/L in the steroid group while levels decreased from 870&#x000a0;&#x000b1;&#x000a0;904 U/L to 261&#x000a0;&#x000b1;&#x000a0;402 U/L in the placebo group. Similarly, mean AST levels dropped from 1002&#x000a0;&#x000b1;&#x000a0;1130 U/L to 59&#x000a0;&#x000b1;&#x000a0;58 U/L in the steroid group compared to 1898&#x000a0;&#x000b1;&#x000a0;3364 U/L to 140&#x000a0;&#x000b1;&#x000a0;398 U/L in the placebo group.</p><p>Accordingly, the trajectories of glutamyl transpeptidase (GGT, <italic>p</italic>&#x000a0;=&#x000a0;0.75), total bilirubin (BIL, <italic>p</italic>&#x000a0;=&#x000a0;0.14), serum albumin (ALB, <italic>p</italic>&#x000a0;=&#x000a0;0.32) and alkaline phosphatase (AP, <italic>p</italic>&#x000a0;=&#x000a0;0.30) within 7 days after transplantation were not different between the two groups.</p><p>The relative risk of mortality in the steroid compared to the placebo group was 0.63 (95% CI [0.29,&#x000a0;1.36], <italic>p</italic>&#x000a0;=&#x000a0;0.31). The relative risk for BCAR in the steroid compared to the placebo arm was 1.02 (95% CI [0.50,&#x000a0;2.10], <italic>p</italic>&#x000a0;=&#x000a0;1.00).</p><p>The probability of survival and BCAR episodes over a follow-up period of 3 years was not statistically different in the two treatment arms (<xref rid="f0015" ref-type="fig">Fig. 3</xref>A and B). In the first year, 6 patients (15%) experienced graft loss in the steroid group <italic>vs.</italic> 10 patients (24%) in the placebo group (<italic>p</italic>&#x000a0;=&#x000a0;0.41). One graft loss in the placebo group did not lead to death because of high urgency retransplantation. Acute rejection within the first 3 months occurred in 10 recipients (24%) in the steroid group <italic>vs.</italic> 10 patients (24%) in the placebo group (<italic>p</italic>&#x000a0;=&#x000a0;1.00).</p><p>We did not find any effect modification for the variables donor age, sex, cold ischemic time, and cause of donor death (<xref rid="f0020" ref-type="fig">Fig. 4</xref>).</p></sec></sec><sec sec-type="discussion" id="s0045"><title>Discussion</title><p>Our study showed that systemic administration of 1000&#x000a0;mg methylprednisolone to the deceased organ donor did not significantly ameliorate liver allograft function or mortality or rejection within the first weeks after engraftment.</p><p>This result is in line with our observation that steroid pretreatment did not reduce the incidence or duration of acute renal transplant failure in kidney allograft recipients <xref rid="b0060" ref-type="bibr">[12]</xref>. On the other hand, this finding contradicts a similar trial that has claimed a protective positive effect of steroid treatment in deceased donor liver transplantation <xref rid="b0065 b0070" ref-type="bibr">[13,14]</xref>. It is therefore essential to try to explain these distinct results of both studies.</p><p>First, it seems necessary to clarify whether steroid administration was effective in terms of suppression of inflammation in the donor organ. To address this question, we have previously shown in kidney transplants, using genome wide expression profiling, that steroid treatment results in a pronounced suppression of inflammation/immune response-associated genes <xref rid="b0060 b0075 b0080 b0085" ref-type="bibr">[12,15&#x02013;17]</xref>. These data suggest that dose and timing of the blinded intervention were chosen correctly and randomization worked fine.</p><p>Furthermore, different experimental parameters between both trials could eventually explain varying outcomes. Administration of the corticosteroid was somewhat different since, in our study, donors received one single shot of 1000&#x000a0;mg whereas Kotsch <italic>et al.</italic> applied 250&#x000a0;mg initially followed by continuous infusion of 100&#x000a0;mg/h. In addition, the primary study end points were transaminases levels on day one post-transplantation in the trial of Kotsch <italic>et al.</italic> while the present study evaluated the trajectories of transaminases as a more stable measurement of a treatment effect. Another difference was the number of study sites, which has an effect on the balance of internal and external validity, i.e. generalizability of findings. Both studies found no significant differences between rejection rates <xref rid="b0065" ref-type="bibr">[13]</xref>.</p><p>Our study, however, was not powered to detect a statistical difference of transaminase trajectories between groups below 0.65. We considered a smaller difference in transaminase trajectories not to be of sound clinical significance. Donor organ quality determined by donor age, which predicts early and long term outcome <xref rid="b0090" ref-type="bibr">[18]</xref>, was not different between groups. A definitive strength of our study is the evaluation of the steroid intervention on hard study end points such as mortality and biopsy-confirmed rejection over a 3-year period.</p><p>In summary, liver ischemia reperfusion injury is obviously by far more complex than expected, so that a reductionist view limiting interventions to steroid pretreatment does not seem to be successful. Thus, although the brain death-related immune response might play an essential role during ischemia reperfusion injury and subsequent transplant dysfunction, it seems that this immune response itself is not a causative factor but that other factors must exist. Further efforts are therefore required in order to significantly improve ischemia reperfusion injury in the context of liver transplantation.</p></sec><sec id="s0050"><title>Conflict of interest</title><p>The authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript.</p></sec><sec id="s0055"><title>Trial registration</title><p>Controlled-trials.com number <ext-link ext-link-type="uri" xlink:href="ctgov:ISRCTN78828338">ISRCTN78828338</ext-link>.</p></sec></body><back><ref-list><title>References</title><ref id="b0005"><label>1</label><mixed-citation publication-type="other">EUROTRANSPLANT. Eurotransplant International Foundation Annual Report 2009, 2010. Available from: <ext-link ext-link-type="uri" xlink:href="http://wwweurotransplantorg">http://wwweurotransplantorg</ext-link>.</mixed-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fernandez-Merino</surname><given-names>F.J.</given-names></name><name><surname>Nuno-Garza</surname><given-names>J.</given-names></name><name><surname>Lopez-Hervas</surname><given-names>P.</given-names></name><name><surname>Lopez-Buenadicha</surname><given-names>A.</given-names></name><name><surname>Quijano-Collazo</surname><given-names>Y.</given-names></name><name><surname>Vicente-Lopez</surname><given-names>E.</given-names></name></person-group><article-title>Donor age as a risk factor for patient survival in the liver transplant</article-title><source>Transplant Proc</source><volume>35</volume><year>2003</year><fpage>1795</fpage><lpage>1797</lpage><pub-id pub-id-type="pmid">12962798</pub-id></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busuttil</surname><given-names>R.W.</given-names></name><name><surname>Tanaka</surname><given-names>K.</given-names></name></person-group><article-title>The utility of marginal donors in liver transplantation</article-title><source>Liver Transpl</source><volume>9</volume><year>2003</year><fpage>651</fpage><lpage>663</lpage><pub-id pub-id-type="pmid">12827549</pub-id></element-citation></ref><ref id="b0020"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hariharan</surname><given-names>S.</given-names></name><name><surname>Johnson</surname><given-names>C.P.</given-names></name><name><surname>Bresnahan</surname><given-names>B.A.</given-names></name><name><surname>Taranto</surname><given-names>S.E.</given-names></name><name><surname>McIntosh</surname><given-names>M.J.</given-names></name><name><surname>Stablein</surname><given-names>D.</given-names></name></person-group><article-title>Improved graft survival after renal transplantation in the United States, 1988 to 1996</article-title><source>N Engl J Med</source><volume>342</volume><year>2000</year><fpage>605</fpage><lpage>612</lpage><pub-id pub-id-type="pmid">10699159</pub-id></element-citation></ref><ref id="b0025"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terasaki</surname><given-names>P.I.</given-names></name><name><surname>Cecka</surname><given-names>J.M.</given-names></name><name><surname>Gjertson</surname><given-names>D.W.</given-names></name><name><surname>Takemoto</surname><given-names>S.</given-names></name></person-group><article-title>High survival rates of kidney transplants from spousal and living unrelated donors</article-title><source>N Engl J Med</source><volume>333</volume><year>1995</year><fpage>333</fpage><lpage>336</lpage><pub-id pub-id-type="pmid">7609748</pub-id></element-citation></ref><ref id="b0030"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kusaka</surname><given-names>M.</given-names></name><name><surname>Pratschke</surname><given-names>J.</given-names></name><name><surname>Wilhelm</surname><given-names>M.J.</given-names></name><name><surname>Ziai</surname><given-names>F.</given-names></name><name><surname>Zandi-Nejad</surname><given-names>K.</given-names></name><name><surname>Mackenzie</surname><given-names>H.S.</given-names></name></person-group><article-title>Activation of inflammatory mediators in rat renal isografts by donor brain death</article-title><source>Transplantation</source><volume>69</volume><year>2000</year><fpage>405</fpage><lpage>410</lpage><pub-id pub-id-type="pmid">10706051</pub-id></element-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pratschke</surname><given-names>J.</given-names></name><name><surname>Neuhaus</surname><given-names>P.</given-names></name><name><surname>Tullius</surname><given-names>S.G.</given-names></name></person-group><article-title>What can be learned from brain-death models?</article-title><source>Transpl Int</source><volume>18</volume><year>2005</year><fpage>15</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">15612978</pub-id></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pratschke</surname><given-names>J.</given-names></name><name><surname>Wilhelm</surname><given-names>M.J.</given-names></name><name><surname>Kusaka</surname><given-names>M.</given-names></name><name><surname>Basker</surname><given-names>M.</given-names></name><name><surname>Cooper</surname><given-names>D.K.</given-names></name><name><surname>Hancock</surname><given-names>W.W.</given-names></name></person-group><article-title>Brain death and its influence on donor organ quality and outcome after transplantation</article-title><source>Transplantation</source><volume>67</volume><year>1999</year><fpage>343</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">10030276</pub-id></element-citation></ref><ref id="b0045"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Hoeven</surname><given-names>J.A.</given-names></name><name><surname>Ploeg</surname><given-names>R.J.</given-names></name><name><surname>Postema</surname><given-names>F.</given-names></name><name><surname>Molema</surname><given-names>I.</given-names></name><name><surname>de Vos</surname><given-names>P.</given-names></name><name><surname>Girbes</surname><given-names>A.R.</given-names></name></person-group><article-title>Induction of organ dysfunction and up-regulation of inflammatory markers in the liver and kidneys of hypotensive brain dead rats: a model to study marginal organ donors</article-title><source>Transplantation</source><volume>68</volume><year>1999</year><fpage>1884</fpage><lpage>1890</lpage><pub-id pub-id-type="pmid">10628769</pub-id></element-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>S.</given-names></name><name><surname>Kotsch</surname><given-names>K.</given-names></name><name><surname>Francuski</surname><given-names>M.</given-names></name><name><surname>Reutzel-Selke</surname><given-names>A.</given-names></name><name><surname>Mantouvalou</surname><given-names>L.</given-names></name><name><surname>Klemz</surname><given-names>R.</given-names></name></person-group><article-title>Brain death activates donor organs and is associated with a worse I/R injury after liver transplantation</article-title><source>Am J Transplant</source><volume>7</volume><year>2007</year><fpage>1584</fpage><lpage>1593</lpage><pub-id pub-id-type="pmid">17430397</pub-id></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hauser</surname><given-names>P.</given-names></name><name><surname>Schwarz</surname><given-names>C.</given-names></name><name><surname>Mitterbauer</surname><given-names>C.</given-names></name><name><surname>Regele</surname><given-names>H.M.</given-names></name><name><surname>Muhlbacher</surname><given-names>F.</given-names></name><name><surname>Mayer</surname><given-names>G.</given-names></name></person-group><article-title>Genome-wide gene-expression patterns of donor kidney biopsies distinguish primary allograft function</article-title><source>Lab Invest</source><volume>84</volume><year>2004</year><fpage>353</fpage><lpage>361</lpage><pub-id pub-id-type="pmid">14704720</pub-id></element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kainz</surname><given-names>A.</given-names></name><name><surname>Wilflingseder</surname><given-names>J.</given-names></name><name><surname>Mitterbauer</surname><given-names>C.</given-names></name><name><surname>Haller</surname><given-names>M.</given-names></name><name><surname>Burghuber</surname><given-names>C.</given-names></name><name><surname>Perco</surname><given-names>P.</given-names></name></person-group><article-title>Steroid pretreatment of organ donors to prevent postischemic renal allograft failure: a randomized, controlled trial</article-title><source>Ann Intern Med</source><volume>153</volume><year>2010</year><fpage>222</fpage><lpage>230</lpage><pub-id pub-id-type="pmid">20713790</pub-id></element-citation></ref><ref id="b0065"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotsch</surname><given-names>K.</given-names></name><name><surname>Ulrich</surname><given-names>F.</given-names></name><name><surname>Reutzel-Selke</surname><given-names>A.</given-names></name><name><surname>Pascher</surname><given-names>A.</given-names></name><name><surname>Faber</surname><given-names>W.</given-names></name><name><surname>Warnick</surname><given-names>P.</given-names></name></person-group><article-title>Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial</article-title><source>Ann Surg</source><volume>248</volume><year>2008</year><fpage>1042</fpage><lpage>1050</lpage><pub-id pub-id-type="pmid">19092349</pub-id></element-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miki</surname><given-names>C.</given-names></name><name><surname>Gunson</surname><given-names>B.K.</given-names></name><name><surname>Buckels</surname><given-names>J.A.</given-names></name><name><surname>Uchida</surname><given-names>K.</given-names></name><name><surname>Mohri</surname><given-names>Y.</given-names></name><name><surname>Kusunoki</surname><given-names>M.</given-names></name></person-group><article-title>Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation</article-title><source>Ann Surg</source><volume>250</volume><year>2009</year><fpage>502</fpage><lpage>503</lpage><comment>author reply 503&#x02013;504</comment><pub-id pub-id-type="pmid">19730189</pub-id></element-citation></ref><ref id="b0075"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilflingseder</surname><given-names>J.</given-names></name><name><surname>Kainz</surname><given-names>A.</given-names></name><name><surname>Muhlberger</surname><given-names>I.</given-names></name><name><surname>Perco</surname><given-names>P.</given-names></name><name><surname>Langer</surname><given-names>R.</given-names></name><name><surname>Kristo</surname><given-names>I.</given-names></name></person-group><article-title>Impaired metabolism in donor kidney grafts after steroid pretreatment</article-title><source>Transpl Int</source><volume>23</volume><year>2010</year><fpage>796</fpage><lpage>804</lpage><pub-id pub-id-type="pmid">20149158</pub-id></element-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lund</surname><given-names>T.</given-names></name><name><surname>Fosby</surname><given-names>B.</given-names></name><name><surname>Korsgren</surname><given-names>O.</given-names></name><name><surname>Scholz</surname><given-names>H.</given-names></name><name><surname>Foss</surname><given-names>A.</given-names></name></person-group><article-title>Glucocorticoids reduce pro-inflammatory cytokines and tissue factor in vitro and improve function of transplanted human islets in vivo</article-title><source>Transpl Int</source><volume>21</volume><year>2008</year><fpage>669</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">18346012</pub-id></element-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ansari</surname><given-names>A.W.</given-names></name><name><surname>Schmidt</surname><given-names>R.E.</given-names></name><name><surname>Heiken</surname><given-names>H.</given-names></name></person-group><article-title>Prednisolone mediated suppression of HIV-1 viral load strongly correlates with C-C chemokine CCL2: in vivo and in vitro findings</article-title><source>Clin Immunol</source><volume>125</volume><year>2007</year><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">17707134</pub-id></element-citation></ref><ref id="b0090"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fruhauf</surname><given-names>N.R.</given-names></name><name><surname>Fischer-Frohlich</surname><given-names>C.L.</given-names></name><name><surname>Kutschmann</surname><given-names>M.</given-names></name><name><surname>Schmidtmann</surname><given-names>I.</given-names></name><name><surname>Kirste</surname><given-names>G.</given-names></name></person-group><article-title>Joint impact of donor and recipient parameters on the outcome of liver transplantation in Germany</article-title><source>Transplantation</source><volume>92</volume><year>2011</year><fpage>1378</fpage><lpage>1384</lpage><pub-id pub-id-type="pmid">22067269</pub-id></element-citation></ref></ref-list><ack><title>Acknowledgments</title><p>This study was supported by grants from the <funding-source id="GS1">Austrian Science Fund</funding-source> (FWF P-18325, FWF P-21436) and the <funding-source id="GS2">Austrian Academy of Science</funding-source> (OELZELT EST370/04) to R.O. We acknowledge the valuable contribution of the OPO coordinators.</p></ack></back><floats-group><fig id="f0005"><label>Fig. 1</label><caption><p><bold>CONSORT flowchart of organ donor and liver graft recipients</bold>.</p></caption><graphic xlink:href="gr1"/></fig><fig id="f0010"><label>Fig. 2</label><caption><p><bold>Trajectories of liver function parameters in the first week after transplantation</bold>. Mean values and standard errors of mean from day 1 to day 7 after transplantation are shown for (A) alanine transaminase (ALT) (<italic>p</italic>&#x000a0;=&#x000a0;0.40), (B) aspartate transaminase (AST) (<italic>p</italic>&#x000a0;=&#x000a0;0.13), (C) glutamyl transpeptidase (GGT) (<italic>p</italic>&#x000a0;=&#x000a0;0.75), (D) serum albumin (ALB) (<italic>p</italic>&#x000a0;=&#x000a0;0.32), (E) total bilirubin (BIL) (<italic>p</italic>&#x000a0;=&#x000a0;0.14) and (F) alkaline phosphatase (AP) (<italic>p</italic>&#x000a0;=&#x000a0;0.30).</p></caption><graphic xlink:href="gr2"/></fig><fig id="f0015"><label>Fig. 3</label><caption><p><bold>Kaplan&#x02013;Meier estimates of (A) survival (<italic>p</italic></bold>&#x000a0;<bold>=</bold>&#x000a0;<bold>0.24) and (B) biopsy-confirmed rejection (log-rank <italic>p</italic></bold>&#x000a0;<bold>=</bold>&#x000a0;<bold>0.96) risks are shown for steroid pretreated livers and placebo</bold>. The number of subjects at risk is provided above the x-axis. Given <italic>p</italic> values were derived from log-rank tests. BCAR, biopsy-confirmed rejection; TX, transplantation.</p></caption><graphic xlink:href="gr3"/></fig><fig id="f0020"><label>Fig. 4</label><caption><p><bold>Graft loss by various donor characteristics</bold>. Indicated <italic>p</italic> values represent the interaction between treatment and characteristics.</p></caption><graphic xlink:href="gr4"/></fig><table-wrap id="t0005" position="float"><label>Table 1</label><caption><p><bold>Demographic data of donors and recipients stratified by treatment</bold>.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td><inline-graphic xlink:href="fx1.gif"/></td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup><italic>p</italic>&#x000a0;=&#x000a0;0.04 (Fisher&#x02019;s exact test).</p></fn></table-wrap-foot></table-wrap></floats-group></article>